转甲状腺素蛋白淀粉样心肌病:从病因到新型治疗
本文综述转甲状腺素蛋白淀粉样心肌病(ATTR-CM)的病理生理机制与治疗进展,提出体内淀粉样蛋白生成与自然清除失衡可能驱动疾病进展的假说。TTR稳定剂(如tafamidis和acoramidis)通过促进循环TTR四聚体构象减缓功能下降并延长生存,TTR基因沉默剂和基因编辑疗法减少淀粉样蛋白生成,但均不增强清除已沉积淀粉样蛋白的能力。靶向TTR淀粉样蛋白的单克隆抗体早期临床试验提示被动免疫治疗可能逆转疾病进展并改善心功能。
要点
- TTR稳定剂促进TTR四聚体构象,减缓功能下降并延长生存。
- TTR基因沉默剂和基因编辑减少淀粉样蛋白生成,但不增强清除已沉积蛋白。
- 靶向TTR淀粉样蛋白的单克隆抗体早期试验提示可能逆转进展并改善心功能。
核心结论
- ATTR-CM的管理需进一步阐明淀粉样蛋白形成、结构与功能影响、清除机制及心肌逆重构之间的复杂相互作用。
研究设计与样本
- 本文为综述,检索范围未在摘要中报告。
主要发现
- TTR稳定剂如tafamidis和acoramidis通过促进循环TTR四聚体构象减缓功能下降并延长生存。
- TTR基因沉默剂抑制肝脏TTR合成,基因编辑疗法nexiguran ziclumeran提供减少淀粉样蛋白生成的额外策略。
- 上述方法不增强机体清除已沉积淀粉样蛋白的有限能力,需加速淀粉样蛋白清除的新药。
- 靶向TTR淀粉样蛋白的单克隆抗体正在开发,早期临床试验提示被动免疫治疗可能逆转疾病进展并改善心功能。
- 体内淀粉样蛋白生成与自然清除失衡驱动疾病进展的假说仍需验证。
临床怎么用
- TTR稳定剂可用于减缓ATTR-CM功能下降并延长生存。
- 基因沉默剂和基因编辑疗法可减少淀粉样蛋白生成,但不清除已沉积蛋白。
- 靶向TTR淀粉样蛋白的单克隆抗体尚处早期试验阶段,需进一步验证。
局限性
- 淀粉样蛋白生成与清除失衡的假说仍需验证。
- 靶向TTR淀粉样蛋白的单克隆抗体证据来自早期临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disorder marked by amyloid deposition in the heart, ultimately impairing cardiac function. Recent treatment advances have paralleled an evolving understanding of ATTR-CM pathophysiology. One emerging hypothesis suggests that an imbalance between in vivo amyloid production and natural clearance may drive disease progression, a conceptual framework that still requires validation. Transthyretin (TTR) stabilizers, such as tafamidis and acoramidis, mitigate amyloid formation by promoting the native tetrameric conformation of circulating TTR, thereby slowing functional decline and prolonging survival. Similarly, TTR gene silencers inhibit hepatic TTR synthesis, and gene-editing therapy with nexiguran ziclumeran offers an additional strategy to reduce amyloid production. However, these approaches do not enhance the body's limited capacity to clear existing amyloid deposits, underscoring the need for novel agents that accelerate amyloid removal. Promisingly, monoclonal antibodies targeting TTR amyloid are under development, with early clinical trials suggesting that this passive immunotherapy may reverse disease progression and improve heart function. Ultimately, optimal management of ATTR-CM will require further elucidation of the complex interplay between amyloid formation, its structural and functional impacts, its clearance mechanisms, and the potential for myocardial reverse remodelling.
引用
- Fontana M, Aimo A, Emdin M, et al. Transthyretin amyloid cardiomyopathy: from cause to novel treatments. Eur Heart J. 2026. PMID: 41030053. doi:10.1093/eurheartj/ehaf667
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。